Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma.
10.3760/cma.j.issn.0253-2727.2023.10.005
- Author:
Teng YU
1
;
Hui LIU
1
;
Wen LEI
1
;
Pan Pan CHEN
1
;
Ai Qi ZHAO
1
;
Xiang Gui YUAN
1
;
Ji Min GAO
2
;
Wen Bin QIAN
1
Author Information
1. Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
2. Wenzhou Medical University Laboratory Medicine, Wenzhou 325035, China.
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor T cells;
Immune checkpoint inhibitor;
Immune related adverse reaction;
Large B-cell lymphoma
- MeSH:
Humans;
Antibodies, Monoclonal/therapeutic use*;
Antigens, CD19;
Chemokine CCL19;
Immunotherapy, Adoptive;
Interleukin-7;
Lymphoma, Large B-Cell, Diffuse/therapy*;
Programmed Cell Death 1 Receptor;
Receptors, Chimeric Antigen
- From:
Chinese Journal of Hematology
2023;44(10):820-824
- CountryChina
- Language:Chinese
-
Abstract:
Objective: This study systematically explore the efficacy and safety of fourth-generation chimeric antigen receptor T-cells (CAR-T), which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19, in relapsed or refractory large B-cell lymphoma. Methods: Our center applied autologous 7×19 CAR-T combined with tirelizumab to treat 11 patients with relapsed or refractory large B-cell lymphoma. The efficacy and adverse effects were explored. Results: All 11 enrolled patients completed autologous 7×19 CAR-T preparation and infusion. Nine patients completed the scheduled six sessions of tirolizumab treatment, one completed four sessions, and one completed one session. Furthermore, five cases (45.5%) achieved complete remission, and three cases (27.3%) achieved partial remission with an objective remission rate of 72.7%. Two cases were evaluated for disease progression, and one died two months after reinfusion because of uncontrollable disease. The median follow-up time was 31 (2-34) months, with a median overall survival not achieved and a median progression-free survival of 28 (1-34) months. Two patients with partial remission achieved complete remission at the 9th and 12th months of follow-up. Therefore, the best complete remission rate was 63.6%. Cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome were controllable, and no immune-related adverse reactions occurred. Conclusion: Autologous 7×19 CAR-T combined with tirelizumab for treating relapsed or refractory large B-cell lymphoma achieved good efficacy with controllable adverse reactions.
